This inventor holds 3 USPTO granted patents. Top assignee: Sloan-Kettering Institute for Cancer Research. Active years: 1995-1996.
Location History:
- New York, NY (US) (1995 - 1996)
- Boulogne-Billancourt, FR (1996)
Company Filing History:
Years Active: 1995-1996
Title: Yves Queneau: Innovator in Cancer Research
Introduction
Yves Queneau is a prominent inventor based in New York, NY (US). He has made significant contributions to the field of cancer research, particularly through his work on the synthesis of important anticancer agents. With a total of 3 patents to his name, Queneau's innovations have the potential to impact cancer treatment significantly.
Latest Patents
Queneau's latest patents focus on the total synthesis of taxol, a well-known anticancer drug. The first patent provides two basic routes for the total synthesis of taxol, along with the intermediates produced in the processes. These intermediates and analogs to taxol may prove to be valuable anticancer agents. The second patent expands on this work by providing three basic routes for the total synthesis of taxol and its analogues, including nortaxol. This research is crucial for developing new treatments for cancer.
Career Highlights
Yves Queneau is affiliated with the Sloan-Kettering Institute for Cancer Research, where he conducts his groundbreaking research. His work has garnered attention in the scientific community, and he is recognized for his innovative approaches to synthesizing complex molecules.
Collaborations
Queneau has collaborated with notable scientists in his field, including Samuel J. Danishefsky and William G. Bornmann. These collaborations have further enhanced the impact of his research and contributed to advancements in cancer treatment.
Conclusion
Yves Queneau's contributions to cancer research through his innovative patents highlight the importance of scientific inquiry in developing effective treatments. His work continues to inspire future research in the field of oncology.